Effects of maternal magnesium sulfate treatment on newborns.
eclampsia
enteral nutrition
magnesium sulfate
neonate
pregnancy-induced hypertension
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
03
03
2021
received:
16
10
2020
accepted:
09
04
2021
pubmed:
28
4
2021
medline:
27
1
2022
entrez:
27
4
2021
Statut:
ppublish
Résumé
Antenatal magnesium sulfate (MgSO The clinical data of 77 infants born to mothers treated with MgSO The serum Mg level of the infants correlated with that of the mothers but not with the duration of Mg treatment or the cumulative dose of Mg. There were no significant differences in the infants' clinical variables according to either the duration of Mg treatment or the cumulative dose of Mg. By contrast, enteral feeding tolerance began at a significantly later age and the heart rate on admission was significantly lower in infants with a serum Mg level ≥4.0 mmol/L than in those with a serum Mg level <4.0 mmol/L. Modest effects on the clinical variables of infants with higher serum Mg levels were determined, whereas neither the duration of Mg treatment nor the cumulative Mg dose correlated with the clinical variables of the infants. Thus, in newborns with only moderately elevated serum Mg levels, serious adverse effects are unlikely.
Sections du résumé
BACKGROUND
BACKGROUND
Antenatal magnesium sulfate (MgSO
METHODS
METHODS
The clinical data of 77 infants born to mothers treated with MgSO
RESULTS
RESULTS
The serum Mg level of the infants correlated with that of the mothers but not with the duration of Mg treatment or the cumulative dose of Mg. There were no significant differences in the infants' clinical variables according to either the duration of Mg treatment or the cumulative dose of Mg. By contrast, enteral feeding tolerance began at a significantly later age and the heart rate on admission was significantly lower in infants with a serum Mg level ≥4.0 mmol/L than in those with a serum Mg level <4.0 mmol/L.
CONCLUSIONS
CONCLUSIONS
Modest effects on the clinical variables of infants with higher serum Mg levels were determined, whereas neither the duration of Mg treatment nor the cumulative Mg dose correlated with the clinical variables of the infants. Thus, in newborns with only moderately elevated serum Mg levels, serious adverse effects are unlikely.
Substances chimiques
Magnesium Sulfate
7487-88-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14747Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 18ek0109265h0002
Organisme : JSPS KAKENHI
ID : JP18K07890
Organisme : JSPS KAKENHI
Informations de copyright
© 2021 Japan Pediatric Society.
Références
Das M, Chaudhuri PR, Mondal BC, Mitra S, Bandyopadhyay D, Pramanik S. Assessment of serum magnesium levels and its outcome in neonates of eclamptic mothers treated with low-dose magnesium sulfate regimen. Indian J. Pharmacol. 2015; 47: 502-8.
Sherwin CM, Baich A, Campbell SC et al. Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations. Basic Clin. Pharmacol. Toxicol. 2014; 114: 318-22.
Marret S, Ancel PY. Neuroprotection for preterm infants with antenatal magnesium sulphate. J. Gynecol. Obstet. Biol. Reprod. (Paris). 2016; 45(10): 1418-33.
Oddie S, Tuffnell DJ, McGuire W. Antenatal magnesium sulfate: Neuro-protection for preterm infants. Arch. Dis. Fetal Neonatal Ed. 2015; 6: F553-7.
Gano D, Ho ML, Partridge JC et al. Antenatal exposure to magnesium sulfate is associated with reduced cerebellar hemorrhage in preterm newborns. J. Pediatr. 2016; 178: 68-74.
Belden MK, Gnadt S, Ebert A. Effects of maternal magnesium sulfate treatment on neonatal feeding tolerance. J. Pediatr. Pharmacol. Ther. 2017; 22(2): 112-7.
Zeng X, Xue Y, Tian Q, Sun R, An R. Effects and safety of magnesium sulfate on neuroprotection: A meta-analysis based on PRISMA guidelines. Medicine 2016; 95(1): 1-12.
Abbassi Ghanavati M, Alexander JM, Mclntire DD, Savani RC, Leveno KJ. Neonatal effects of magnesium sulfate given to the mother. Am. J. Perinatal. 2012; 29: 795-9.
Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrance Database Syst. Rev. 2002; 8: CD001060.
American College of Obstetricians and Gynecologists’ Committee on Practice. Bulletins. Practice Bulletin No. 172: Premature rupture of membranes. Obstet. Gynecol. 2016; 128(4): 165-77.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013; 48: 452-8.
Scudiero R, Khoshnood B, Pryde PG, Lee KS, Wall S, Mittendorf R. Perinatal death and tocolytic magnesium sulfate. Obstet. Gynecol. 2000; 96: 178-82.
Drassinower D, Friedman AM, Levin H, Obican SG, Gyamifi-Bannerman C. Does magnesium exposure affect neonatal resuscitation? Am. J. Obstet. Gynecol. 2015; 213: e1-5.
McNamara HC, Crowther CA, Brown J. Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour. Cochrane Database Syst. Rev. 2015; 12: CD011200.
Cardosi RJ, Chez RA. Magnesium sulfate, maternal hypothermia, and fetal bradycardia with loss of heart rate variability. Obstet. Gynecol. 1998; 92: 691-3.
Duffy CR, Odibo AO, Roehi KA, Macones GA, Cahill AG. Effects of magnesium sulfate on fetal heart rate patterns in the second stage of labor. Obstet. Gynecol. 2012; 119(6): 1129-36.
Ramsey PS, Rouse DJ. Magnesium sulfate as a tocolytic agent. Semin. Perinatol. 2001; 25: 236-47.
Chesley LC. Parenteral magnesium sulfate and the distribution, plasma levels, and excretion of magnesium. Am. J. Obstet. Gynecol. 1979; 133(1): 1-7.
Cruikshank DP, Pitkin RM, Donnelly E, Reynolds WA. Urinary magnesium, calcium, and phosphate excretion during magnesium sulfate infusion. Obstet. Gynecol. 1981; 58: 430-4.
Holcomb WL, Shackelford GD, Petrie RH. Magnesium tocolysis and neonatal bone abnormalities. A controlled study. Obstet. Gynecol. 1991; 78: 611-4.
Matsuda Y, Maeda Y, Ito M et al. Effect of magnesium sulfate treatment on neonatal bone abnormalities. Gynecol. Obstet. Invest. 1977; 44: 82-8.
Santi MD, Henry GW, Douglas GL. Magnesium sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J. Pediatr. Orthop. 1994; 14: 249-53.